China: China FDA Calls For Comments On Key Policy Proposals

On May 11-12, 2017, the China FDA (CFDA) issued four new draft policies for public comments, proposing further reforms in the current drug and medical device regulatory regime. The four draft policies aim to accelerate the review and approval of new drug and medical device applications (Circular No. 52), deregulate the conduct of clinical trials to encourage innovation (Circular No. 53), enhance post-market supervision throughout a product's entire life cycle (Circular No. 54), and protect the rights of innovators (Circular No. 55). The CFDA is soliciting public comments until June 10, 2017. Further legislative initiatives will be arranged if any parts of the draft policies contradict the current CFDA regulations. These draft policies, if adopted, are likely to further streamline and accelerate the market access of innovative products and will have a far-reaching impact on China's life sciences industry.

I. Circular No. 52 proposes the following key measures to accelerate the review and approval of new products:

  • Expedited reviews and approvals for urgently needed therapies. Drugs and devices that offer new solutions for treating life-threatening diseases or address critical unmet medical needs can be eligible for conditional approvals, as long as early and mid-stage study data can indicate their efficacy and predict their clinical values. Companies receiving conditional approvals must develop a risk management plan and initiate confirmatory post-approval study as per the requirements in the conditional approvals. Innovative drugs and devices sponsored by the National Science and Technology Major Project can be eligible for expedited review and approval.
  • Supportive regime for rare disease cures. Drugs and devices that offer new solutions for treating rare diseases, if already approved outside China, can be eligible for conditional approvals. Companies can complete the necessary stages of clinical study after receiving marketing authorizations. The health authorities will publish a catalogue of rare diseases and establish a rare disease patient registry.
  • Cross-disciplinary and professionalized review system. The technical review for new drugs and devices will be led by a team of cross-disciplinary reviewers. Each new drug and device application will be assigned to a dedicated managing reviewer, who will be responsible for scheduling consultation meetings. The CFDA will require consultation meetings at all critical milestones of clinical studies, i.e., prior to initiation of phase I, after completion of phase II (and prior to initiation of phase III), after completion of phase III, and prior to the NDA application. Consultation meetings with expert panels will also be required to deliberate important but controversial technical questions. The technical review conclusions will be published in public, with an exception of company confidential information.
  • Market access benefits. Hospitals will be encouraged to prioritize their procurement and use of new drugs with definite efficacy and reasonable prices. The government will support inclusion of innovative drugs in the basic medical insurance scheme, and the reimbursable drug list will be updated more frequently.

II. Circular No. 53 proposes the following new measures to remove certain governmental controls over clinical studies on new drugs and devices:

  • Expansion of clinical study infrastructure
    • Currently, hospitals need to be certified by the CFDA and the National Health and Family Planning Commission in order to become qualified clinical study sites. The draft policy proposed to revoke the certification system. All medical institutions that have the necessary infrastructure to conduct clinical studies can file for record with the CFDA. The CFDA will supervise clinical study sites through rigorous clinical study audits, and will not admit data generated in those studies that fail the audits.
    • Hospitals, medical research institutions and academic institutions will be incentivized to actively participate in clinical studies and research. The capabilities and quality of clinical studies and research will be considered for hospitals' and physicians' performance reviews and ratings.
    • Foreign companies and research institutions will be allowed to conduct phase I new drug clinical trials in China.
  • Improvement in ethics committee reviews.
    • Currently, ethics committee (EC) review and approval is subsequent to the Center for Drug Evaluation (CDE)'s clinical trial authorization process. According to the proposed policy, companies can apply for EC review and approval in parallel to clinical trial applications, provided that the clinical study protocols are approved by the EC before the submission of clinical trial applications.
    • The proposed policy encourages mutual recognition of EC approvals. In the event of multi-center studies, the lead site's EC approval can be used as the basis for all EC reviews. The ECs of other participating sites can directly endorse the EC approval of the lead site, without repetitive reviews.
    • In addition to hospital-affiliated ECs, the proposed policy intends to encourage the formation of regional ECs, which will be responsible for the supervision of clinical studies, qualification of investigators, and the adjudication of appeals filed by sponsors or investigators. 
  • Streamlining clinical trial approval process. Like the IND mechanism in the U.S., companies need to submit a clinical trial application to the CDE, but only need to wait for 60 working days before initiating the study, unless the CDE rejects the application or issues a deficiency notice during the 60-day period. For certain high-risk medical devices that are subject to the clinical trial approval process, the CFDA must give its review opinions within 60 working days upon receiving the clinical trial application. Applicants will be automatically approved to conduct trials if the Center for Medical Device Evaluation (CMDE) does not reject the application or issue a deficiency notice during the 60-day period.
  • Admission of foreign study data. Foreign clinical data can be admitted to support registration of drugs and medical devices in China, as long as (a) the trials comply with Chinese regulations, (b) the trials pass CFDA's on-site audits, and (c) applicants can provide clinical data to prove that no ethnicity difference affects the product's safety and efficacy.
  • Expanded access to investigational products. Expanded access to investigational products may be allowed in phase II and phase III trials where the drug or device (a) is intended for treating life-threatening diseases with no effective treatments, and (b) shows probable benefits in early studies. Only a limited number of patients (not exceeding the number of study subjects as per the approved protocol) at each site can have such compassionate use upon their informed consent. The safety data generated can be used to support marketing authorizations.

III. Circular No. 54 reinforces the CFDA's determination to enhance post-approval enforcement.

  • Roll out the Marketing Authorization Holder (MAH) system. The MAH system has been piloted in 10 provinces since November 2015. MAHs are required to take all legal responsibilities for pre-clinical study, clinical studies, product manufacturing, quality of APIs and excipients, distribution, clinical use and adverse event reporting pertaining to the approved drugs. Meanwhile, contractual research, manufacturing, and service organizations (CRO, CMO, CSO, etc.) that are retained by MAHs are required to take both regulatory responsibilities by law and contractual liabilities. The CFDA is determined to roll out the MAH system nationwide.
  • Improve adverse event reporting system. The CFDA will levy the primary adverse event reporting responsibilities and post-market product evaluation duties on the MAHs. Conception, delayed reporting, or misrepresentation will be severely punished by the CFDA.
  • Introduce regular and rigorous audits and inspections
    • The CFDA will further strengthen its data integrity assessment of regulatory dossiers, continue its on-site audits on clinical trials, and take legal actions against data forgery (including criminal investigations by the police and prosecutors).
    • The CFDA and local FDAs will strengthen risk-based, on-site inspections and for-cause inspections for GxP compliance through the product's life cycle, and build a professional team of inspectors through recruiting and training initiatives.
  • Regulate promotional activities. The CFDA will establish a Medical Representative Registration System, where all drug license holders will need to register their medical representatives. Medical representatives are allowed to conduct only academic promotion and technical consultation when interacting with physicians and are prohibited from engaging in drug sales.
  • Enhance the infrastructure for technical reviews. The CFDA will procure services from qualified third parties to meet the capacity requirement for drug and device reviews. In addition, the CFDA plans to establish an Electronic Common Technical Document (eCTD) system to standardize the format of electronic submissions of drug and device applications. It aims to create a database of master files for each approved drug and device. Last but not least, the CFDA will step up its efforts toward international harmonization of technical standards and hopes to achieve mutual recognition of review and approval decisions.

IV. Circular No. 55 proposes to establish a patent linkage system and improve regulatory data protection. It also reiterates the confidentiality obligations of all government employees involved in the review and approval process.

  • Establish patent linkage system. NDA applicants must submit a statement of patents pertinent to their drugs and either (i) an affidavit of non-infringement or (ii) a notice to relevant patent holders if the drugs may infringe any patents within 20 days after the submission of NDA applications. Patent holders can file infringement litigation within 20 days after receiving the notice or upon their knowledge of the CFDA's acceptance of the NDA applications, and inform the CDE accordingly. The CFDA can stay its NDA application for a period of up to 24 months from the date of receiving proof of court acceptance of the case, but the CDE can continue its technical review during this period. If the parties settle or a final court decision is issued during the 24-month period, the CFDA can reject or approve the NDA applications based on the settlement agreement or the court decision. If the court does not issue any judgement after the 24-month period expires, the CFDA can approve the NDA applications.
  • Improve regulatory data protection. NDA applicants can apply for regulatory data protection along with their submissions. The length of protection ranges from 1.5 years to 10 years starting from the date of NDA issuance, according to the degree of novelty and the therapeutic areas. The CDE will not approve NDAs for the same drugs during the protection period, except if the applicants can prove that they generate their data independently.
  • Establish a "China Orange Book." The CFDA will publish a "China Orange Book" listing all approved drugs in China. The listing will contain the registration category of the approved drugs and their active ingredients, dosage forms, specifications, MAHs, and other regulatory exclusivity entitlements (i.e., patents, new drug monitoring periods, and regulatory data protection periods).

These draft CFDA policies introduce fundamental changes to the regulatory paradigm, and will considerably reshape the China strategy of life sciences companies. Companies need to carefully review the new policies, propose comments, and monitor the legislative progress.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.